Immunotech Biopharm Ltd (6978.HK)

3,030 -0,070 (-2,26%) Alla chiusura: 04:08PM HKT

Immunotech Biopharm Ltd

Guosheng Technology Park
8th Floor, Block 1 No.1 Kangding Street Beijing Eco-Tech Dev Area
Beijing
China

https://www.eaal.net

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 211

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Zheng Tan	Executive Chairman	2,87M	N/D	1978
Dr. Yu Wang	CEO, CTO & Executive Director	2,76M	N/D	1968
Mr. Hyun Chul Jung	Founder & Chief Strategy Officer	652,86k	N/D	1964
Mr. Ning Yang	CFO & Company Secretary	N/D	N/D	1982
Dr. Yu Zhang	Chief Scientist	N/D	N/D	1964
Mr. Jian Zhang	Senior Vice President	N/D	N/D	1971

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for non-hodgkin lymphoma; and TCR-T cell series products to treat solid tumors. Further, the company's pre-clinical products include aT19 to treat acute lymphoblastic leukaemia; CAR-T-43 for T cell leukaemia and T cell lymphoma; CAR-T-22 for B lymphocyte leukaemia; CAR-T-BCMA to treat multiple myeloma; CAR-T-ENX for solid tumors; TCR800 to treat renal cancer; and EBV, CMV specific T cells for EBV/CMV infection. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

Governance aziendale

L'ISS Governance QualityScore di Immunotech Biopharm Ltd al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.